Natalie Xu

Suggest Changes
Learn More
PURPOSE A randomized phase II trial (E1200) was designed to assess toxicities and surgical resection rates in two neoadjuvant gemcitabine-based chemoradiation regimens in patients with borderline(More)
  • 1